Status:
COMPLETED
Double-Blind Randomized Cross-Over Trial Comparing Metabolic Effects of Candesartan, Hydrochlorothiazide and Placebo
Lead Sponsor:
Umeå University
Collaborating Sponsors:
Sahlgrenska University Hospital
AstraZeneca
Conditions:
Hypertension
Obesity
Eligibility:
All Genders
18-70 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to investigate the effect of a 12-week candesartan treatment compared with hydrochlorothiazide on insulin sensitivity assessed with hyperinsulinemic euglycemic clamp.
Detailed Description
To investigate the mechanisms underlaying the diabetes-preventing effect of candesartan with respect to possible impact on insulin sensitivity, beta cell function and adipose tissue function and distr...
Eligibility Criteria
Inclusion
- Male and female 18-70 years old
- Diagnosed hypertension and abdominal obesity (waist circumference greater than or equal to 102 cm (M) or 88 cm (F)
Exclusion
- Uncontrolled hypertension
- Treatment with more than two concomitant antihypertensive medications
- Diabetes Mellitus
- Other endocrine disorder
- Severe liver disease
- Severely reduced renal function
- Malignant disease
- Alcohol or drug abuse
- Severe psychiatric illness
- History of stroke, myocardial infarction, unstable angina pectoris, participation in another clinical trial less than two months prior to screening visit
- treatment with anti-obesity drugs
- anti-inflammatory drugs or immunosuppressive drugs
Key Trial Info
Start Date :
April 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2006
Estimated Enrollment :
26 Patients enrolled
Trial Details
Trial ID
NCT00282178
Start Date
April 1 2005
End Date
April 1 2006
Last Update
October 16 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Umeå University Hospital
Umeå, Sweden, SE-90185